Related Experiment Video
Updated: May 28, 2026

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
Published on: February 20, 2017
Microtubule-binding protein CLIP-170 is a mediator of paclitaxel sensitivity
Xiaodong Sun1, Dengwen Li, Yunfan Yang
1Department of Genetics and Cell Biology, Tianjin Key Laboratory of Protein Science, College of Life Sciences, Nankai University, Tianjin 300071, China.
Abstract:
CLIP-170 is a microtubule-binding protein and participates in diverse microtubule-associated cellular activities by regulating microtubule dynamics. Here we provide evidence that CLIP-170 is a mediator of the sensitivity of the anti-microtubule drug paclitaxel in breast cancer. In vitro cell proliferation assays reveal that CLIP-170 expression in breast cancer cell lines correlates with their sensitivity to paclitaxel. In addition, CLIP-170 expression in clinical samples of breast cancer correlates with the pathological response of tumours to paclitaxel-containing chemotherapy. Mitotic index and caspase-3 activity analyses reveal that CLIP-170 increases the abilities of paclitaxel to block cell cycle progression at mitosis and to induce apoptosis in breast cancer cells. By microtubule sedimentation assay and binding affinity analysis, we further find that CLIP-170 promotes paclitaxel binding to microtubules. In vitro tubulin polymerization assay shows that CLIP-170 enhances the activity of paclitaxel to promote microtubule assembly. These results demonstrate that CLIP-170 mediates paclitaxel sensitivity in breast cancer via a microtubule-dependent mechanism.
Insights
Cytoplasmic linker-associated protein 170 (CLIP-170) enhances breast cancer cell sensitivity to paclitaxel. CLIP-170 promotes paclitaxel
Area of Science:
- Molecular Biology
- Cancer Research
- Pharmacology
Background:
- Microtubule-binding proteins regulate microtubule dynamics and cellular activities.
- Paclitaxel is a key anti-microtubule drug used in breast cancer chemotherapy.
Purpose of the Study:
- To investigate the role of CLIP-170 in mediating paclitaxel sensitivity in breast cancer.
- To elucidate the mechanism by which CLIP-170 influences paclitaxel efficacy.
Main Methods:
- In vitro cell proliferation assays using breast cancer cell lines.
- Analysis of clinical breast cancer samples for CLIP-170 expression and treatment response.
- Mitotic index and caspase-3 activity assays.
- Microtubule sedimentation assays and binding affinity analysis.
- In vitro tubulin polymerization assays.
Main Results:
- CLIP-170 expression in breast cancer cell lines correlates with paclitaxel sensitivity.
- CLIP-170 expression in clinical samples correlates with response to paclitaxel chemotherapy.
- CLIP-170 enhances paclitaxel-induced mitotic arrest and apoptosis.
- CLIP-170 promotes paclitaxel binding to microtubules and enhances paclitaxel-induced microtubule assembly.
Conclusions:
- CLIP-170 acts as a mediator of paclitaxel sensitivity in breast cancer.
- The mechanism involves CLIP-170's role in paclitaxel-microtubule interactions and microtubule dynamics.
- CLIP-170 represents a potential therapeutic target for improving paclitaxel efficacy in breast cancer treatment.
Related Concept Videos
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules
Microtubule Associated Proteins (MAPs)
Destabilization of Microtubules
Microtubule Formation

